2023. Lebrikizumab Provides Stable Itch Response With No or Minimal Fluctuations up to One Year in Patients With Atopic Dermatitis. SKIN The Journal of Cutaneous Medicine. 7, 6 (Nov. 2023), s282. DOI:https://doi.org/10.25251/skin.7.supp.282.